The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $45.17

Today's change-1.93 -4.10%
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $45.17

Today's change-1.93 -4.10%
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc down (U.S.)$1.93

Sarepta Therapeutics Inc closed sharply lower Friday, dropping (U.S.)$1.93 or 4.10% to (U.S.)$45.17. Shares have lost 2.88% over the last five days, but have gained 64.67% over the last year to date. This security has underperformed the S&P 500 by 40.84% during the last year.

Key company metrics

  • Open(U.S.) $46.97
  • Previous close(U.S.) $47.10
  • High(U.S.) $46.97
  • Low(U.S.) $45.03
  • Bid / Ask(U.S.) $44.15 / (U.S.) $46.00
  • YTD % change+64.67%
  • Volume1,822,315
  • Average volume (10-day)2,027,630
  • Average volume (1-month)2,216,382
  • Average volume (3-month)2,328,943
  • 52-week range(U.S.) $26.26 to (U.S.) $63.73
  • Beta1.03
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.44
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue351650
Total other revenue--------
Total revenue351650
Gross profit34165--
Total cost of revenue100--
Total operating expense98569457
Selling / general / administrative36262322
Research & development59297134
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)3------
Other operating expenses, total--------
Operating income-63-39-88-57
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets0125----
Other--------
Income before tax-6386-88-57
Income after tax-6384-88-57
Income tax, total02----
Net income-6384-88-57
Total adjustments to net income--------
Net income before extra. items-6384-88-57
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-6384-88-57
Inc. avail. to common incl. extra. items-6384-88-57
Diluted net income-6384-88-57
Dilution adjustment--------
Diluted weighted average shares55565548
Diluted EPS excluding extraordinary itemsvalue per share-1.151.50-1.62-1.18
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-1.110.05-1.62-1.18